The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Challenges and opportunities of drug repositioning
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor
Butrynski, J. E., D'Adamo, D. R., Hornick, J. L., Dal Cin, P., Antonescu, C. R., Jhanwar, S. C., Ladanyi, M., Capelletti, M., Rodig, S. J., Ramaiya, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007056 · Cited by 870
Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
DiMasi, J. A., Feldman, L., Seckler, A., & Wilson, A. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.295 · Cited by 845
Drug repurposing from an academic perspective
Oprea, T. I., Bauman, J. E., Bologa, C. G., Buranda, T., Chigaev, A., Edwards, B. S., Jarvik, J. W., Gresham, H. D., Haynes, M. K., Hjelle, B., et al. (2011) · Drug Discovery Today: Therapeutic Strategies · doi:10.1016/j.ddstr.2011.10.002 · Cited by 364
From patients to partners: participant-centric initiatives in biomedical research
Kaye, J., Curren, L., Anderson, N., Edwards, K., Fullerton, S. M., Kanellopoulou, N., Lund, D., MacArthur, D. G., Mascalzoni, D., Shepherd, J., et al. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3218 · Cited by 293
Rare diseases and orphan drugs
Melnikova, I. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3654 · Cited by 213
Drug repositioning: Re-investigating existing drugs for new therapeutic indications
Padhy, B., & Gupta, Y. (2011) · Journal of Postgraduate Medicine · doi:10.4103/0022-3859.81870 · Cited by 206
Thalidomide: A review of approved and investigational uses
Matthews, S. J., & McCoy, C. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80085-1 · Cited by 203
The value of drug repositioning in the current pharmaceutical market
Tobinick, E. L. (2009) · Drug News & Perspectives · doi:10.1358/dnp.2009.22.2.1303818 · Cited by 193
Cited by
Drug repurposing: a promising tool to accelerate the drug discovery process
Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.06.014 · Cited by 597
Deep-Learning-Based Drug–Target Interaction Prediction
Wen, M., Zhang, Z., Niu, S., Sha, H., Yang, R., Yun, Y., & Lu, H. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.6b00618 · Cited by 576
Shaping the interaction landscape of bioactive molecules
Gfeller, D., Michielin, O., & Zoete, V. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt540 · Cited by 501
Jin, G., & Wong, S. T. C. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.005 · Cited by 416
Talevi, A. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00205 · Cited by 381
Recent Developments in Drug Discovery for Leishmaniasis and Human African Trypanosomiasis
Nagle, A. S., Khare, S., Kumar, A. B., Supek, F., Buchynskyy, A., Mathison, C. J. N., Chennamaneni, N. K., Pendem, N., Buckner, F. S., Gelb, M. H., et al. (2014) · Chemical Reviews · doi:10.1021/cr500365f · Cited by 348
Drug-Target Interaction Prediction with Graph Regularized Matrix Factorization
Ezzat, A., Zhao, P., Wu, M., Li, X.-L., & Kwoh, C.-K. (2017) · IEEE/ACM Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2016.2530062 · Cited by 322
Ezzat, A., Wu, M., Li, X.-L., & Kwoh, C.-K. (2019) · Briefings in Bioinformatics · doi:10.1093/bib/bby002 · Cited by 314
A review of computational drug repurposing
Park, K. (2019) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2019.27.2.59 · Cited by 300
Drug repurposing: a systematic review on root causes, barriers and facilitators
Krishnamurthy, N., Grimshaw, A. A., Axson, S. A., Choe, S. H., & Miller, J. E. (2022) · BMC Health Services Research · doi:10.1186/s12913-022-08272-z · Cited by 279
Drug repositioning: Progress and challenges in drug discovery for various diseases
Hua, Y., Dai, X., Xu, Y., Xing, G., Liu, H., Lu, T., Chen, Y., & Zhang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114239 · Cited by 232
“Besides, for an approved drug, not only preclinical information but also clinical profiles are also available, which accelerates the development of drug discovery [4].”
On the Integration of In Silico Drug Design Methods for Drug Repurposing
March-Vila, E., Pinzi, L., Sturm, N., Tinivella, A., Engkvist, O., Chen, H., & Rastelli, G. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00298 · Cited by 235
Design of efficient computational workflows for in silico drug repurposing
Vanhaelen, Q., Mamoshina, P., Aliper, A. M., Artemov, A., Lezhnina, K., Ozerov, I., Labat, I., & Zhavoronkov, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.09.019 · Cited by 150
Enabling Precision Cardiology Through Multiscale Biology and Systems Medicine
Johnson, K. W., Shameer, K., Glicksberg, B. S., Readhead, B., Sengupta, P. P., Björkegren, J. L. M., Kovacic, J. C., & Dudley, J. T. (2017) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2016.11.010 · Cited by 83
Artificial intelligence facilitates drug design in the big data era
Wang, L., Ding, J., Pan, L., Cao, D., Jiang, H., & Ding, X. (2019) · Chemometrics and Intelligent Laboratory Systems · doi:10.1016/j.chemolab.2019.103850 · Cited by 80
Kortüm, B., Radhakrishnan, H., Zincke, F., Sachse, C., Burock, S., Keilholz, U., Dahlmann, M., Walther, W., Dittmar, G., Kobelt, D., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02407-6 · Cited by 26
Metadata
- Authors
- Novac, N.
- Venue
- Trends in Pharmacological Sciences
- Publisher
- Elsevier BV
- Published
- 2013-05
- Volume
- 34
- Issue
- 5
- Pages
- 267-272
- ISSN
- 0165-6147 (ISSN-L)
- OpenAlex
- W1968217711
- Cited by
- 374
- References
- 25
- FWCI
- 9.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.